

13448 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

USV PHARMACEUTICAL CORPORATION
1 SCARSDALE ROAD • TUCKAHOE, NEW YORK 10707

HERBERT H. McDADE, JR.
PRESIDENT
CHIEF OPERATING OFFICER

March 11, 1975

The Honorable Senator Gaylord Nelson
Chairman - Monopoly Subcommittee
on the Senate Small Business Committee
The United States Senate
Washington, D. C. 20510

Dear Senator Nelson:

As the discoverer and developer of phenformin, USV Pharmaceutical Corporation has been following the controversy regarding the UGDP study; and, at your invitation, on October 21, 1974 we submitted to your Subcommittee the Company's general policy concerning the appropriate use of hypoglycemic agents, various criticisms of the UGDP study and comments concerning the reports of other groups which have studied these agents.

Our comments, as expressed in that letter, remain the same; however, in reading the transcript of the testimony before your Subcommittee on January 31, 1975, we feel compelled to amplify our previous letter.

The testimony of The Chairman of The Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents reflected the following statement:

"The findings on phenformin, if one can judge from the absence of criticism, appear to have been accepted by medical scientists, even if they have not so far been translated effectively into medical practice. Yet these findings also